排序方式: 共有57条查询结果,搜索用时 805 毫秒
41.
42.
43.
44.
例1男,18岁。左眼看不清2月于1994年12月30日入院。既往无限外伤及眼病史.全身检查无异常。眼部检查:右眼视力1.5,左眼视力0.08。双眼前书无异常,右眼眼底正常。左眼眼底:扔下象很视网膜青灰色隆起.其上有血管爬行,黄斑部轻微水肿.中心反光消失。三面镜不见:3:00~6:00锯齿缘陆离.6:00断离缘可见2个小囊肿。人院诊断:左眼孔源性机网膜脱离(锯齿线断离).1995年1月5日在局麻下行左眼巩股冷凝加硅脏外加压术.术后视网膜复位,术后一周权力0.1。半年后随访左眼视力0.3.例2男,例1之胞兄.22岁.左眼看不清5年,于1995年… 相似文献
45.
目的:运用Meta分析方法对奥硝唑与其他抗茵药物治疗妇科常见阴道感染的临床效果进行评价,为其提供循证医学证据。方法:全面检索奥硝唑与其他抗菌药物治疗妇科阴道感染的临床研究文献,按照Meta分析方法,运用RevMan5.1软件对符合条件的所有结果进行分析。结果:共纳入13篇文献,总样本量1553例,其中,试验组777例,对照组776例。Meta分析结果显示,有效性、临床治愈率、安全性及细菌清除率的合并OR值分别为2.83(P〈0.00001)、2.11(P=0.04)、0.25(P〈0.0001)、1.11(P=0.79),表明奥硝唑的疗效优于对照组,并且不良反应的发生率低于对照组,细菌清除率差异没有统计学意义。结论:在治疗妇科阴道感染中,奥硝唑的疗效和安全性优于其他抗茵药物。 相似文献
46.
一般资料
104例突发性耳聋患者,随机分为治疗组和对照组。治疗组60例中,男38例,女22例;双侧8例,右侧23例,左侧29例;年龄17~56岁;病程2~6天;温邪伤络型23例,痰血瘀阻型20例,肾元亏损型8例,气血虚弱型9例。对照组44例中,男26例,女18例;双侧4例,右侧19例,左侧21例;年龄19~51岁;病程2~8天;温邪伤络型20例,痰血瘀阻型16例,肾元亏损型4例,气血虚弱型4例。 相似文献
48.
目的探讨血清β2-糖蛋白Ⅰ(beta2-glycoproteinⅠ,β2-GPⅠ)在不同时期糖尿病视网膜病变(diabetic retinopathy,DR)患者中的变化,了解血清β2-GPⅠ与DR的关系。方法收集60例2型糖尿病患者血清标本,将其分为3组:20例无明显DR(no-DR,NDR)患者为NDR组;20例非增生性DR(non-proliferative DR,NPDR)患者为NPDR组;20例增生性DR(proliferative DR,PDR)患者为PDR组。同时收集20例健康人血清为正常对照(normal control,NC)组。应用Westernblot方法,对各组随机抽取的4份血清样本中β2-GPⅠ水平进行分析。结果β2-GPⅠ水平在NPDR组、PDR组大量表达,在NDR组中量表达,在NC组少量表达。NC组、NDR组、NPDR组和PDR组各条带面积平均光密度值,分别为(440564.9±66597.4)mm-2、(655561.6±85640.8)mm-2、(859969.7±85461.0)mm-2、(954887.4±125764.4)mm-2。与NC组比较,β2-GPⅠ水平在NDR组、NPDR组、PDR组显著升高,差异均有统计学意义(均为P<0.01);与NDR组比较,β2-GPⅠ水平在NPDR组、PDR组显著升高,差异均有统计学意义(均为P<0.01);与NPDR组比较,PDR组无明显升高,差异无统计学意义(P>0.05)。结论在DR发生过程中,血清β2-GPⅠ水平上调,β2-GPⅠ可能具有潜在的早期诊断DR的价值。 相似文献
49.
50.
Objective:To evaluate the probability and efficacy of endostatin-vascular endothelial growth inhibitor (VEGI) recombinant adenoviruses combined with dexamethasone on suppressing heterolamellar corneal transplantation rejection. Methods: Heterolamellar corneal transplantation models were established in 64 New Zealand rabbits, which were randomized into 4 groups of 16 rabbits each. After the transplantation, all the 64 right eyes were injected subconjunctively with 0. 2 ml saline (saline group), 0. 1 ml AdCA13-hENDO-VEGI151 plus 0. 1 ml saline (AdCA13-hENDO-VEGI151 group), 0. 1 ml Dexamethasone (DXM) plus 0. 1 ml saline (DXM group), 0. 1 ml AdCA13-hENDO-VEGI151 plus 0. 1 ml DXM (Ad-CA13-hENDO-VEGI151 combined with DXM group) with one time each 3 days for 10 times. Graft survival and ocular surface were observed for 6 weeks. The fusion protein expression was detected by immunohistochemistry 6 weeks after transplantation. Results: Both the CNV index, rejection index and the xenograft rejection rate in the AdCA13-hENDO-VEGI151 combined with DXM group were statistically lower than those in other groups. AdCA13-hENDO-VEGI151 combined with DXM group: 1. 375 0±0. 500 0, 2. 750 0 ±1. 843 9 and 6. 25% respectively 6 week after keratoplasty; Saline group: 3. 437 5±0. 512 3, 8. 812 5± 1.1087, 100.00%; AdCAl3-hENDO-VEGI151 group: 2. 312 5±0. 478 7, 5. 625 0±0. 957 4, 62.50%; DXM group: 3. 000 0±0. 816 5, 5. 562 5±1. 315 0, 56.25% (P<0. 01). Immunohistochemical staining showed the fusion protein expressed mainly in corneal epithelium. Conclusion: The fusion protein expressed by the recombinant adenovirus has significant effect on inhibiting neovascularization after heterolamellar corneal transplantation. The topical application of AdCA13-hENDO-VEGI151 combined with DXM suppressed effectively the postoperative xenograft rejection rate of heterolamellar corneal transplantation. 相似文献